Abstract
KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
CNS & Neurological Disorders - Drug Targets
Title:Role of KCa3.1 Channels in CNS Diseases: A Concise Review
Volume: 15 Issue: 10
Author(s): Sinoy Sugunan, Sreekala S. Nampoothiri, Tanya Garg and Rajanikant G. Krishnamurthy
Affiliation:
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
Abstract: KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Export Options
About this article
Cite this article as:
Sugunan Sinoy, Nampoothiri S. Sreekala, Garg Tanya and Krishnamurthy G. Rajanikant, Role of KCa3.1 Channels in CNS Diseases: A Concise Review, CNS & Neurological Disorders - Drug Targets 2016; 15 (10) . https://dx.doi.org/10.2174/1871527315666160822111913
| DOI https://dx.doi.org/10.2174/1871527315666160822111913 |
Print ISSN 1871-5273 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7- Trimethylxanthine Hydrazones with In-vitro Neuroprotective and MAO-B Inhibitory Activities
Medicinal Chemistry Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Child and Adolescent Mental Health in Pakistan
Adolescent Psychiatry Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Plasma Nesfatin-1 and Obestatin Levels in Patients with Type 2 Diabetes Mellitus
Current Pharmaceutical Design EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation
Current Stem Cell Research & Therapy Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Recent Developments in Mass Spectrometry Analysis of Phosphoproteomes
Current Proteomics Neuroinflammation and Ageing: Current Theories and an Overview of the Data
Reviews on Recent Clinical Trials Cognitive Abilities of Alzheimers Disease Transgenic Mice are Modulated by Social Context and Circadian Rhythm
Current Alzheimer Research Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism





